Today: 29 April 2026
Browse Category

NYSE:OSCR 3 October 2025 - 10 February 2026

Oscar Health stock rises in premarket after 2026 revenue outlook; House subpoenas add a fresh risk

Oscar Health stock rises in premarket after 2026 revenue outlook; House subpoenas add a fresh risk

Oscar Health shares rose 3.3% to $12.66 in premarket trading after forecasting 2026 revenue of $18.7–$19.0 billion and operating earnings of $250–$450 million. The company posted a wider Q4 net loss of $353 million and a medical loss ratio of 95.4%. A U.S. House panel subpoenaed Oscar and other insurers over ACA subsidy practices. Oscar also disclosed a new $475 million revolving credit facility.
10 February 2026
·
Oscar Health Stock (OSCR) News Today: ACA Subsidy Cliff, Analyst Price Targets, and 2026 Open Enrollment Signals (Dec. 15, 2025)

Oscar Health Stock (OSCR) News Today: ACA Subsidy Cliff, Analyst Price Targets, and 2026 Open Enrollment Signals (Dec. 15, 2025)

Oscar Health shares traded near $16.63 on December 15, 2025, as the ACA open enrollment deadline coincided with new analyst coverage and policy debate in Washington. Congress is weighing the fate of enhanced ACA premium tax credits set to expire at the end of 2025. KFF projects average subsidized premiums could more than double in 2026 if subsidies lapse. Oscar’s business is heavily exposed to these ACA marketplace shifts.
15 December 2025
·
Oscar Health (OSCR) Stock Today: Fresh Analyst Coverage, Big 2027 Profit Hopes and Policy Risk in Focus

Oscar Health (OSCR) Stock Today: Fresh Analyst Coverage, Big 2027 Profit Hopes and Policy Risk in Focus

Oscar Health shares traded near $15.80 on Thursday after closing at $15.59, down 8% despite broader market gains. Stephens & Co. initiated coverage with an “Equal-Weight” rating and a $17 price target. Analyst targets now range from $11 to $25, with volatility metrics remaining elevated. The stock’s 52-week range is $11.20 to $23.80, and market cap stands at about $4.1 billion.
11 December 2025
·
Oscar Health (OSCR) Stock Soars on Piper Sandler Upgrade and ACA Tailwinds – What to Know on November 26, 2025

Oscar Health (OSCR) Stock Soars on Piper Sandler Upgrade and ACA Tailwinds – What to Know on November 26, 2025

Oscar Health shares jumped 8–9% to about $18.20 by mid-afternoon Wednesday, November 26, 2025, with volume topping 10 million shares. The surge followed a Piper Sandler upgrade to “Overweight” and a new $25 price target, citing Oscar’s margin strategy and earnings potential even if ACA subsidies lapse. Earlier in November, major banks had maintained bearish ratings and lower targets.
26 November 2025
··
Oscar Health (OSCR) Stock Soars on Obamacare Subsidy Hopes as AI-Powered Virtual Care Rewrites Its Growth Story

Oscar Health (OSCR) Stock Soars on Obamacare Subsidy Hopes as AI-Powered Virtual Care Rewrites Its Growth Story

Oscar Health shares rose as much as 20% in premarket trading Monday after reports that the White House may propose a two-year extension of enhanced ACA subsidies, with new eligibility limits. The stock traded at $15.47, up about 15% as of 7:56 a.m. ET, according to RTTNews. Oscar recently reported Q3 revenue up 23% year over year to $2.93 billion and membership above 2 million.
24 November 2025
···
Oscar Health (OSCR) launches 2026 South Florida plans, adds ‘HelloMeno’; stock in focus — Nov. 10, 2025

Oscar Health (OSCR) launches 2026 South Florida plans, adds ‘HelloMeno’; stock in focus — Nov. 10, 2025

Oscar Health announced new individual-market plans for Miami-Dade and four nearby South Florida counties, effective January 1, 2026, with enrollment via HealthCare.gov. The company also introduced HelloMeno, a menopause-focused plan with Elektra Health, available in multiple states for 2026. Managed-care stocks fell after Trump criticized ACA subsidies, pressuring marketplace insurers.
10 November 2025
··
Oscar Health (OSCR) Q3 2025: ~$3.0B Revenue, EPS Beats, 2025 Guidance Reaffirmed; Balance Sheet Simplified via Note Exchange — Nov. 6, 2025

Oscar Health (OSCR) Q3 2025: ~$3.0B Revenue, EPS Beats, 2025 Guidance Reaffirmed; Balance Sheet Simplified via Note Exchange — Nov. 6, 2025

Oscar Health reported Q3 revenue of $2.99 billion, up 23% year-over-year but below analyst estimates. The company posted a net loss of $137.5 million, or –$0.53 per share, beating EPS expectations. Medical loss ratio rose to 88.5%. Oscar exchanged $187.5 million of 2031 notes for about 23.3 million shares and reaffirmed its 2025 outlook.
6 November 2025
··
Oscar Health Stock Skyrockets on AI-Fuelled Growth Plans – Analysts Warn of ACA Risks

Oscar Health Stock Skyrockets on AI-Fuelled Growth Plans – Analysts Warn of ACA Risks

Oscar Health shares jumped 11% to $21.50 on Oct. 3, 2025, and traded near $21.76 on Oct. 14, up roughly 40% year-to-date. The company announced a $410 million convertible debt offering to fund AI initiatives and launched a new employer health plan with Hy-Vee. Q2 revenue rose to about $2.9 billion, but net losses widened to $228 million. Analysts remain bearish, with an average price target near $12.
17 October 2025
··
Oscar Health (OSCR) Stock Surges on Expansion Plans – What Analysts Are Saying

Oscar Health (OSCR) Stock Skyrockets on ACA Hopes and Tech-Driven Growth – Can the Insurtech Finally Turn a Profit?

Oscar Health closed at $22.30 on Oct. 6, 2025, with a market cap near $5.6 billion after surging 42% year-to-date. Q2 revenue rose 29% to $2.86 billion, but the company posted a $228 million net loss as its medical loss ratio jumped to 91.1%. Membership topped 2 million. Wall Street consensus remains “Strong Sell,” with an average 12-month price target of $12.
6 October 2025
·
Oscar Health (OSCR) Stock Surges on Expansion Plans – What Analysts Are Saying

Oscar Health (OSCR) Stock Surges on Expansion Plans – What Analysts Are Saying

Oscar Health shares traded near $19.81 midday Oct. 3, up about 2.8%, with a market cap around $4.9 billion. The company reported Q2 revenue of $2.86 billion and a $228 million net loss, serving about 2 million members, mostly in ACA exchanges. On Sep. 11, Oscar announced a $350 million convertible note offering to fund growth and retire its credit line. Analyst ratings remain cautious, with recent downgrades citing ACA risk.
3 October 2025
·

Stock Market Today

  • QQQ Gains 0.3% Led by NXPI's 25% Surge, Analyst Price Targets Highlight Optimism
    April 29, 2026, 1:00 PM EDT. The Nasdaq-100 ETF $QQQ rose 0.3%, boosted by a 25.1% jump in $NXPI shares. Other major contributors included $INTC (up 10%) and $STX (up 13.7%). Insider trading data showed heavy selling activity by NXPI executives, with 13 sales versus 1 purchase in six months. Despite insider sales, analyst sentiment remains positive, with two recent buy ratings and a median price target of $257.5. Top price targets range from $235 to $345, reflecting optimistic outlooks on NXPI's prospects. Investors are watching these signals closely as $QQQ's tech-heavy composition remains influenced by strong individual stock moves.

Latest article

Silicon Motion Stock Jumps After Q1 Sales Double and AI Storage Outlook Tops Estimates

Silicon Motion Stock Jumps After Q1 Sales Double and AI Storage Outlook Tops Estimates

29 April 2026
Silicon Motion reported first-quarter revenue of $342.1 million, up 105% from a year earlier, and forecast second-quarter sales above Wall Street estimates. Shares rose $45.09 to $194.27 in New York trading. The company cited strong demand for embedded storage controllers and AI-related enterprise storage. CEO Wallace Kou said its MonTitan SSD controller platform will enter volume production this quarter.
Starbucks Stock Surges After Earnings Beat Makes Niccol’s Turnaround Look Real

Starbucks Stock Surges After Earnings Beat Makes Niccol’s Turnaround Look Real

29 April 2026
Starbucks raised its fiscal 2026 outlook after global comparable store sales rose 6.2% in the second quarter, beating analyst estimates. Shares jumped about 10% to $107.03. North American operating margin fell to 9.9% from 11.6% due to higher labor and product costs. The company now expects at least 5% comparable sales growth for the year.
Teradyne Stock Slides After Record AI Quarter. The Guidance Is Why.

Teradyne Stock Slides After Record AI Quarter. The Guidance Is Why.

29 April 2026
Teradyne shares fell 16% to $319.10 Wednesday after the chip-testing company forecast lower second-quarter revenue and profit, despite posting record first-quarter sales of $1.282 billion, up 87% from a year earlier. About 70% of revenue came from AI-related demand, but management warned of “lumpy growth” due to large customer programs.
Go toTop